Literature DB >> 25533111

Targeting novel signaling pathways for resistant acute myeloid leukemia.

Kathleen M Sakamoto1, Steven Grant2, Diana Saleiro3, John D Crispino3, Nobuko Hijiya4, Francis Giles3, Leonidas Platanias5, Elizabeth A Eklund5.   

Abstract

Acute myeloid leukemia (AML) is a hematologic malignancy that is the most common type of acute leukemia diagnosed in adults and the second most common type in children. The overall survival is poor and treatment is associated with significant complications and even death. In addition, a significant number of patients will not respond to therapy or relapse. In this review, several new signaling proteins aberrantly regulated in AML are described, including CREB, Triad1, Bcl-2 family members, Stat3, and mTOR/MEK. Identifying more effective and less toxic agents will provide novel approaches to treat AML.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Novel therapies; Resistance; Signaling pathways

Mesh：

Substances：

Year:  2014        PMID： 25533111      PMCID： PMC4355162          DOI： 10.1016/j.ymgme.2014.11.017

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN： 1096-7192            Impact factor:   4.797


  93 in total

1.  MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Authors:  M Konopleva; M Milella; P Ruvolo; J C Watts; M R Ricciardi; B Korchin; T McQueen; W Bornmann; T Tsao; P Bergamo; D H Mak; W Chen; J McCubrey; A Tafuri; M Andreeff
Journal:  Leukemia       Date:  2011-11-08       Impact factor: 11.528

2.  Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia.

Authors:  H A Drabkin; C Parsy; K Ferguson; F Guilhot; L Lacotte; L Roy; C Zeng; A Baron; S P Hunger; M Varella-Garcia; R Gemmill; F Brizard; A Brizard; J Roche
Journal:  Leukemia       Date:  2002-02       Impact factor: 11.528

3.  Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

Authors:  Nicolas Chapuis; Jerome Tamburini; Alexa S Green; Christine Vignon; Valerie Bardet; Aymeric Neyret; Melanie Pannetier; Lise Willems; Sophie Park; Alexandre Macone; Sauveur-Michel Maira; Norbert Ifrah; François Dreyfus; Olivier Herault; Catherine Lacombe; Patrick Mayeux; Didier Bouscary
Journal:  Clin Cancer Res       Date:  2010-09-30       Impact factor: 12.531

4.  3p21 is a recurrent treatment-related breakpoint in myelodysplastic syndrome and acute myeloid leukemia.

Authors:  G Shi; H J Weh; S Martensen; D Seeger; D K Hossfeld
Journal:  Cytogenet Cell Genet       Date:  1996

Review 5.  Recent progress toward epigenetic therapies: the example of mixed lineage leukemia.

Authors:  Tobias Neff; Scott A Armstrong
Journal:  Blood       Date:  2013-05-06       Impact factor: 22.113

6.  BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.

Authors:  Stephanie Beurlet; Nader Omidvar; Petra Gorombei; Patricia Krief; Carole Le Pogam; Niclas Setterblad; Pierre de la Grange; Christophe Leboeuf; Anne Janin; Maria-Elena Noguera; Florence Hervatin; Laure Sarda-Mantel; Marina Konopleva; Michael Andreeff; Andrea W Tu; Alice C Fan; Dean W Felsher; Anthony Whetton; Marika Pla; Robert West; Pierre Fenaux; Christine Chomienne; Rose Ann Padua
Journal:  Blood       Date:  2013-08-13       Impact factor: 22.113

7.  Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.

Authors:  Kerstin Maria Kampa-Schittenhelm; Michael Charles Heinrich; Figen Akmut; Katharina Henriette Rasp; Barbara Illing; Hartmut Döhner; Konstanze Döhner; Marcus Matthias Schittenhelm
Journal:  Mol Cancer       Date:  2013-05-24       Impact factor: 27.401

Review 8.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

9.  The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo.

Authors:  S C Nabinger; X J Li; B Ramdas; Y He; X Zhang; L Zeng; B Richine; J D Bowling; S Fukuda; S Goenka; Z Liu; G-S Feng; M Yu; G E Sandusky; H S Boswell; Z-Y Zhang; R Kapur; R J Chan
Journal:  Leukemia       Date:  2012-10-22       Impact factor: 11.528

Review 10.  STAT inhibitors for cancer therapy.

Authors:  Muhammad Furqan; Akintunde Akinleye; Nikhil Mukhi; Varun Mittal; Yamei Chen; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-12-05       Impact factor: 17.388
View more
  28 in total

Review 1.  [Advances in targeted therapy for childhood acute myeloid leukemia].

Authors:  Ni-Na Wang; Qi-Dong Ye
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-07

2.  Role of alternative polyadenylation dynamics in acute myeloid leukaemia at single-cell resolution.

Authors:  Congting Ye; Qian Zhou; Yiling Hong; Qingshun Quinn Li
Journal:  RNA Biol       Date:  2019-03-13       Impact factor: 4.652

3.  Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.

Authors:  Ewa M Kosciuczuk; Diana Saleiro; Barbara Kroczynska; Elspeth M Beauchamp; Frank Eckerdt; Gavin T Blyth; Sameem M Abedin; Francis J Giles; Jessica K Altman; Leonidas C Platanias
Journal:  Blood       Date:  2016-06-15       Impact factor: 22.113

4.  The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents.

Authors:  Yan Yu; Yangchun Xie; Lizhi Cao; Liangchun Yang; Minghua Yang; Michael T Lotze; Herbert J Zeh; Rui Kang; Daolin Tang
Journal:  Mol Cell Oncol       Date:  2015-05-26

5.  Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling.

Authors:  Si-Qi He; Meng Gao; Yun-Feng Fu; Ya-Nan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia.

Authors:  Samy A F Morad; Traci S Davis; Mark Kester; Thomas P Loughran; Myles C Cabot
Journal:  Leuk Res       Date:  2015-07-02       Impact factor: 3.156

7.  Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.

Authors:  Samy A F Morad; Terence E Ryan; P Darrell Neufer; Tonya N Zeczycki; Traci S Davis; Matthew R MacDougall; Todd E Fox; Su-Fern Tan; David J Feith; Thomas P Loughran; Mark Kester; David F Claxton; Brian M Barth; Tye G Deering; Myles C Cabot
Journal:  J Lipid Res       Date:  2016-05-02       Impact factor: 5.922

8.  Neuropilin-1 contributes to esophageal squamous cancer progression via promoting P65-dependent cell proliferation.

Authors:  F Shi; L Shang; L-Y Yang; Y-Y Jiang; X-M Wang; J-J Hao; Y Zhang; D-K Huang; Y Cai; X Xu; Q-M Zhan; X-M Jia; Y Cao; M-R Wang
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

9.  A Predictive Based Regression Algorithm for Gene Network Selection.

Authors:  Stéphane Guerrier; Nabil Mili; Roberto Molinari; Samuel Orso; Marco Avella-Medina; Yanyuan Ma
Journal:  Front Genet       Date:  2016-06-15       Impact factor: 4.599

10.  Modeling pediatric AML FLT3 mutations using CRISPR/Cas12a- mediated gene editing.

Authors:  Natalia Rivera-Torres; Kelly Banas; Eric B Kmiec
Journal:  Leuk Lymphoma       Date:  2020-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.